- The sale of 23andMe’s genetic data has prompted a lawsuit from 27 states and the District of Columbia, seeking to block the sale of genetic material the company has collected from 15 million people as part of its operations. The states argue, despite Regeneron’s claims that it will follow 23andMe’s privacy policies and applicable law, genetic data is too personal to be sold without the explicit consent of 23andMe’s customers.
Dozens of state attorneys general have sued to block the sale of 23andMe’s genetic material just as a biotechnology company is seeking to buy the company out of bankruptcy for hundreds of millions of dollars.
